{"custom_id": "Candesartan-Citalopram-Fluphenazine-Histamine H1 receptor_8:upper_bound", "response": "REASON: The question describes a phenothiazine antipsychotic (Fluphenazine) that inhibits a rhodopsin-like GPCR linked to the phospholipase C/IP3 pathway. The Histamine H1 receptor matches this description as it is a rhodopsin-like GPCR activated by histamine (a biogenic amine), signals via Gq/PLC/IP3, and is expressed in the specified tissues. The provided interaction triple explicitly states Fluphenazine inhibits this receptor.\nANSWER: Histamine H1 receptor"}
{"custom_id": "Lamotrigine-Oxaprozin-Sildenafil_4:upper_bound", "response": "REASON: The question describes a drug with a pyrazolopyrimidinone core and N-ethylpiperazine sulfonamide side chain, which matches Sildenafil's structure (SMILES confirms pyrazolopyrimidinone and sulfonamide group). The \u03c0-\u03c0 stacking interaction with Oxaprozin (oxazole-fused propionic acid derivative) is explicitly stated in the DRUG 2-DRUG 3 interaction triple. The indirect connection to Lamotrigine (dichlorophenyl triazine derivative) occurs via Oxaprozin\u2019s hydrogen bond with Lamotrigine. Sildenafil fulfills all structural and interaction criteria.  \nANSWER: Sildenafil"}
{"custom_id": "Ranitidine-Sibutramine-Zolpidem_4:upper_bound", "response": "REASON: The question seeks a drug with an imidazopyridine core substituted with methyl and benzyl groups that engages in \u03c0-\u03c0 stacking with a molecule containing a cyclobutyl ring and a 4-chlorophenyl group. Zolpidem (Drug 3) has an imidazopyridine core (evident in its SMILES structure: fused rings with nitrogen atoms) substituted with a methyl group (from the toluene moiety, CC1=CC=C(C=C1)) and a benzyl-like aromatic group. The interaction triple confirms that Sibutramine (Drug 2), which contains a cyclobutyl ring and 4-chlorophenyl group, interacts with Zolpidem via \u03c0-\u03c0 stacking. \nANSWER: Zolpidem"}
{"custom_id": "Cetirizine-Dipyridamole-Sildenafil-Zaleplon_2:upper_bound", "response": "REASON: The PDE5 inhibitor described is Sildenafil. The sedative-hypnotic nonbenzodiazepine of the pyrazolopyrimidine class is Zaleplon. The interaction triple \"Sildenafil-apoplexy-Zaleplon\" directly indicates that combining Sildenafil (PDE5 inhibitor) with Zaleplon (the specified sedative) results in apoplexy.\nANSWER: Zaleplon"}
{"custom_id": "Alprazolam-Bumetanide-Fenofibrate-Modafinil_5:upper_bound", "response": "REASON: The question describes a drug with a sulfinyl-linked diphenylmethane core and an acetamide group, matching Modafinil's structure (SMILES: C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N). The fibrate derivative (Fenofibrate, with isopropyl [CC(C)] and phenoxy [OC1=CC=CC=C1] moieties) interacts via aromatic \u03c0-\u03c0 stacking, as per the DRUG 3-DRUG 4 interaction triple.  \nANSWER: Modafinil"}
{"custom_id": "alendronic acid-Pyridostigmine_0:upper_bound", "response": "REASON: The drug-drug interaction triple explicitly states that alendronic acid (a bisphosphonate) is associated with gastric inflammation when coadministered with pyridostigmine. Alendronic acid's known gastrointestinal side effects (e.g., acid reflux, abdominal pain) are exacerbated by pyridostigmine's cholinergic effects (increased GI motility and secretions), leading to a heightened risk of gastric inflammation. The triple directly links alendronic acid as the subject causing the adverse effect (gastric inflammation) with pyridostigmine as the interacting object.\nANSWER: alendronic acid"}
{"custom_id": "Ketorolac-Oxaprozin_0:upper_bound", "response": "REASON: The question asks for the medication (used for moderate to severe nociceptive pain with strong prostaglandin inhibition) that may cause gastric inflammation when combined with a propionic acid derivative NSAID (Oxaprozin, indicated for arthritis). Ketorolac is a potent NSAID known for robust prostaglandin synthesis inhibition and gastrointestinal risks. The interaction triple explicitly links Ketorolac with gastric inflammation when combined with Oxaprozin, a propionic acid NSAID.  \nANSWER: Ketorolac"}
{"custom_id": "Naproxen-Doxazosin-Alpha-1B adrenergic receptor_7:upper_bound", "response": "REASON: The question specifies a quinazoline-class drug used for enlarged prostate and hypertension that inhibits a receptor with a characterized inverse agonist complex. Doxazosin, a quinazoline-class \u03b11-adrenergic blocker, treats these conditions and causes hypotension/dizziness. The provided interaction triple links Doxazosin to binding/inhibition of the **Alpha-1B adrenergic receptor**, whose crystal structure with inverse agonist (+)-cyclazosin is documented.  \nANSWER: Alpha-1B adrenergic receptor"}
{"custom_id": "Chloroquine-hydroxychloroquine_3:upper_bound", "response": "REASON: Hydroxychloroquine (DRUG 2) contains a terminal ethanol group (-CCOH) in its ethylamino chain, as indicated by the \"CCO\" segment in its SMILES notation. This -OH group can act as both a hydrogen bond donor and acceptor. Chloroquine (DRUG 1) lacks this group, as its ethylamino chain terminates without an -OH. The additional -OH in hydroxychloroquine allows it to form more hydrogen bonds with interacting partners compared to chloroquine.  \nANSWER: hydroxychloroquine"}
{"custom_id": "Amlodipine-Pamidronic acid-thiotepa_1:upper_bound", "response": "REASON: The anti-cancer medication involved in the second interaction must be the organophosphorus compound causing erythema when co-administered with Pamidronic acid. Thiotepa is explicitly stated as an organophosphorus anti-cancer drug, and the interaction triple \"Pamidronic acid-erythema-thiotepa\" confirms its role in the second reaction.\nANSWER: thiotepa"}
{"custom_id": "Diazepam-Duloxetine-Acamprosate_4:upper_bound", "response": "REASON: Acamprosate (Drug 3) has an acetyl amide (CC(=O)N) and a sulfonic acid (S(=O)(=O)O) group connected via a three-carbon chain (N-C-C-C-S), matching the structural description. Duloxetine (Drug 2) contains a thiophene ring (C1=CC=CS1) linked via an ether (O) to a naphthyl group (C2=CC=CC3=CC=CC=C32). The interaction triple explicitly states \"Duloxetine-Hydrogen Bonding-Acamprosate,\" confirming the hydrogen bond between these two drugs.  \nANSWER: Acamprosate"}
{"custom_id": "Tramadol-Exemestane_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided states that Tramadol (subject) has a pneumonia-related interaction (predicate) with Exemestane (object), which is an aromatase inhibitor used for hormone-receptor-positive breast cancer. The question asks for the drug associated with this interaction when administered concurrently with an aromatase inhibitor. Tramadol is explicitly named as the interacting drug in the triple.\nANSWER: Tramadol"}
{"custom_id": "Haloperidol-Muscarinic acetylcholine receptor M5_6:upper_bound", "response": "REASON: The question specifies a G protein-coupled receptor activated by acetylcholine that inhibits adenylate cyclase and decreases PKA activity. The provided protein background for Muscarinic acetylcholine receptor M5 explicitly states it causes adenylate cyclase inhibition and reduced PKA activity, aligning with the functional description. Haloperidol, a butyrophenone antipsychotic, directly binds and inhibits this receptor according to the drug-protein interaction triple. Despite typical Gq coupling for M5, the given data asserts its role in the described pathway, making it the correct answer.\n\nANSWER: Muscarinic acetylcholine receptor M5"}
{"custom_id": "Alprazolam-Ciclopirox_3:upper_bound", "response": "REASON: The question asks which drug with a triazolobenzodiazepine core (Alprazolam) acts as a hydrogen bond donor/acceptor in interaction with a cyclohexylpyridone-structured drug (Ciclopirox). Alprazolam's structure includes nitrogen atoms in the triazole and benzodiazepine rings, which can act as hydrogen bond acceptors, and NH groups (e.g., in the triazole or diazepine) that can act as donors. Ciclopirox contains a ketone (C=O, acceptor) and hydroxyl (O-H, donor). The interaction triple explicitly states Alprazolam participates in hydrogen bonding with Ciclopirox, confirming its role as the donor/acceptor.\n\nANSWER: Alprazolam"}
{"custom_id": "Norfloxacin-Zolpidem-vincristine-Torasemide_2:upper_bound", "response": "REASON: The antineoplastic agent described (mitotic inhibitor from Catharanthus roseus with neurotoxicity and intrathecal fatality risk) is vincristine. The loop diuretic listed on WHO essential medicines and used for fluid overload is Torasemide. The interaction triple explicitly states \"vincristine-drug toxicity NOS-Torasemide,\" indicating that Torasemide increases vincristine's toxicity. This aligns with the scenario where the diuretic exacerbates adverse effects of the antineoplastic agent.  \nANSWER: Torasemide"}
{"custom_id": "Naproxen-Ondansetron-Salmeterol-Beta-1 adrenergic receptor_8:upper_bound", "response": "REASON: The question describes a long-acting respiratory drug (Salmeterol, a LABA) used via dry-powder inhaler for asthma/COPD. The interaction with ondansetron (a 5-HT3 antagonist) causing cholecystitis aligns with the DRUG 2-DRUG 3 interaction triple. The protein involved must be one Salmeterol binds/activates, expressed in cardiac tissue and cerebral cortex. The DRUG 3-PROTEIN triple specifies Salmeterol binds/activates Beta-1 adrenergic receptor, which matches the cardiac and cerebral cortex expression described. Despite typical \u03b22 selectivity, the provided triples override general knowledge.  \nANSWER: Beta-1 adrenergic receptor"}
{"custom_id": "Cetirizine-Temozolomide_0:upper_bound", "response": "REASON: The question asks for a second-generation antihistamine with lower sedation incidence, associated with erythema when combined with an alkylating agent for gliomas. The provided interaction explicitly links cetirizine and temozolomide causing erythema. While cetirizine has a higher sedation risk than fexofenadine/loratadine among second-gen antihistamines, the question's focus on the specific drug interaction (cetirizine-temozolomide) overrides the sedation comparison discrepancy.  \nANSWER: Cetirizine"}
{"custom_id": "Ziprasidone-Acamprosate_3:upper_bound", "response": "REASON: The question asks which drug acts as a hydrogen bond donor or acceptor in their interaction. Ziprasidone contains an indolinone moiety with a carbonyl oxygen (hydrogen bond acceptor) and a secondary amide NH (hydrogen bond donor). Acamprosate has a sulfonic acid-derived sulfonate group (three oxygen acceptors) and a secondary amide NH (donor). The drug-drug interaction triple specifies \"Ziprasidone-Hydrogen Bonding-Acamprosate,\" implying Ziprasidone participates in hydrogen bonding with Acamprosate. Sulfonate groups (in Acamprosate) are strong hydrogen bond acceptors due to their electronegative oxygens, while Ziprasidone's amide NH can act as a donor. The interaction likely involves Ziprasidone donating a hydrogen bond (via its NH) to Acamprosate\u2019s sulfonate acceptor. Thus, Acamprosate serves as the acceptor in this context.  \nANSWER: Acamprosate"}
{"custom_id": "Orphenadrine-Sumatriptan_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided explicitly states that Orphenadrine interacts with Sumatriptan to cause erythema. Sumatriptan is a 5-HT1B/1D agonist used for migraines, making it the co-administered drug in the question. The adverse reaction (erythema) is attributed to the interaction with Orphenadrine.\nANSWER: Orphenadrine"}
{"custom_id": "Triazolam-Rosiglitazone-Bimatoprost_1:upper_bound", "response": "REASON: The question specifies a thiazolidinedione (PPAR\u03b3 agonist) for diabetes, which is Rosiglitazone (Drug 2). The ophthalmic solution described (for glaucoma and eyelash growth) aligns with Bimatoprost (Drug 3). The interaction triple \"Rosiglitazone-Adenopathy-Bimatoprost\" directly links their co-administration to adenopathy risk.  \nANSWER: Bimatoprost"}
{"custom_id": "Furosemide-melphalan_0:upper_bound", "response": "REASON: The interaction triple provided (Furosemide-Dyspnea exertional-melphalan) indicates that the combination of furosemide and melphalan is associated with exertional dyspnea. While furosemide primarily causes electrolyte imbalances and renal/hepatic concerns, melphalan's role as an alkylating chemotherapy agent is more directly linked to systemic toxicities, including rare pulmonary complications. The documented interaction likely arises from melphalan's potential to cause pulmonary toxicity (e.g., interstitial pneumonitis), which may be exacerbated by furosemide's fluid/electrolyte effects, leading to exertional dyspnea in combination therapy. The question specifies the substance \"newly prescribed,\" which is melphalan, aligning it with the interaction's causality.  \nANSWER: melphalan"}
{"custom_id": "Fentanyl-desvenlafaxine_0:upper_bound", "response": "REASON: The question asks for a drug interacting with a potent synthetic opioid (fentanyl) causing nervous tension. The provided drug-drug interaction triple explicitly links fentanyl and desvenlafaxine with nervous tension as the outcome, indicating their pharmacodynamic interaction.\nANSWER: desvenlafaxine"}
{"custom_id": "Alprazolam-Ciclopirox_0:upper_bound", "response": "REASON: The question specifies a high-affinity triazolobenzodiazepine (anxiety medication) interacting with an antifungal for onychomycosis/seborrheic dermatitis, causing decreased arterial pressure. The provided interaction triple explicitly links **Alprazolam** (DRUG 1) and **Ciclopirox** (DRUG 2) via the predicate \"arterial pressure NOS decreased.\" Alprazolam matches the description of the anxiety medication, and Ciclopirox aligns with the antifungal use case. The answer is the anxiety drug in the interaction.\nANSWER: Alprazolam"}
{"custom_id": "Temazepam-Zafirlukast_3:upper_bound", "response": "REASON: The question describes two drugs. The first has a diazepine ring fused with a chlorinated benzene and phenyl substituent, matching Temazepam's structure (SMILES confirms benzodiazepine core with Cl and phenyl groups). The second drug contains sulfonamide and carbamate groups on a multi-ring backbone, matching Zafirlukast's SMILES. The interaction triple explicitly states Temazepam forms hydrogen bonds with Zafirlukast.\nANSWER: Temazepam"}
{"custom_id": "Ondansetron-Pirbuterol_0:upper_bound", "response": "REASON: The question asks for the asthma medication (short-acting \u03b22 agonist) that may experience a \"loss of weight\" interaction when co-administered with ondansetron (a 5-HT3 receptor antagonist). The provided drug-drug interaction triple explicitly states \"Ondansetron-loss of weight-Pirbuterol,\" confirming Pirbuterol as the affected drug.  \nANSWER: Pirbuterol"}
{"custom_id": "Temazepam-Zafirlukast-Cysteinyl leukotriene receptor 1_7:upper_bound", "response": "REASON: The question refers to a protein mediating allergic reactions via leukotrienes and inhibited by an asthma drug. Zafirlukast, an asthma medication, is described as a leukotriene receptor antagonist targeting CysLT1 (Cysteinyl leukotriene receptor 1). The protein's role aligns with mediating allergic/hypersensitivity reactions through leukotriene binding, and the drug-protein interaction explicitly states Zafirlukast inhibits this receptor.  \nANSWER: Cysteinyl leukotriene receptor 1"}
{"custom_id": "Temazepam-Megestrol-Desloratadine-Darunavir_2:upper_bound", "response": "REASON: The patient is on desloratadine (active metabolite of loratadine) and started darunavir (a protease inhibitor boosted by ritonavir/cobicistat). The interaction triple explicitly links desloratadine and darunavir to acute pancreatitis. Darunavir is the newly added antiretroviral, making it the most likely causative agent based on the provided interaction data.  \nANSWER: Darunavir"}
{"custom_id": "Alprazolam-Benazepril_3:upper_bound", "response": "REASON: Hydrogen bond acceptors are electronegative atoms with lone pairs, such as oxygen or nitrogen. Benazepril (Drug 2) contains multiple oxygen-based acceptor groups: an ethoxycarbonyl group (ester carbonyl oxygen), an amide carbonyl oxygen, and a terminal carboxylic acid (deprotonated as COO\u207b at physiological pH, providing two oxygen acceptors). Alprazolam (Drug 1) primarily has nitrogen atoms in its triazole ring as potential acceptors, but oxygen-based acceptors (e.g., carbonyls) are stronger and more numerous in Benazepril. The drug-drug interaction triple also positions Benazepril as the object of hydrogen bonding, implying it acts as the acceptor. \n\nANSWER: Benazepril"}
{"custom_id": "Diazepam-Doxazosin_3:upper_bound", "response": "REASON: The question describes Drug 1 as having a seven-membered diazepine fused to a benzene ring with a chlorine substituent, matching Diazepam's structure (SMILES confirms the benzodiazepine core with Cl). Drug 2 is described as a quinazoline core substituted with two methoxy groups and a dioxane-linked phenyl moiety, aligning with Doxazosin's structure (SMILES confirms quinazoline, methoxy, and dioxane-phenyl groups). The interaction triple explicitly states a \u03c0-\u03c0 stacking interaction between Diazepam and Doxazosin.\nANSWER: Diazepam"}
{"custom_id": "Risedronic acid-Imatinib_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided states that Risedronic acid is linked to sinus headache when interacting with Imatinib. However, Imatinib's background information explicitly lists cephalalgia (headache) as a known adverse reaction, while Risedronic acid does not. The interaction likely exacerbates Imatinib's pre-existing risk of headache, making Imatinib the agent associated with the increased risk of sinus headache in this scenario.  \nANSWER: Imatinib"}
{"custom_id": "Norfloxacin-Zolpidem_0:upper_bound", "response": "REASON: The question asks for the fluoroquinolone antibiotic linked to folate deficiency when interacting with zolpidem (a nonbenzodiazepine hypnotic). The provided interaction triple explicitly states **Norfloxacin** as the subject causing folate deficiency (predicate) when interacting with **Zolpidem** (object). Norfloxacin matches the description of the fluoroquinolone used for urinary/gynecological infections with tendon-related risks, while Zolpidem is the nonbenzodiazepine hypnotic for insomnia.  \nANSWER: Norfloxacin"}
{"custom_id": "Alprazolam-Bumetanide_0:upper_bound", "response": "REASON: The question specifies a loop diuretic associated with erythema when combined with a potent anxiolytic benzodiazepine (GABA_A receptor agonist). The relevant drug-drug interaction triple explicitly links Alprazolam (the anxiolytic benzodiazepine) and Bumetanide (the loop diuretic) via the erythema predicate.  \nANSWER: Bumetanide"}
{"custom_id": "Celecoxib-Oxaprozin-Sildenafil_1:upper_bound", "response": "REASON: The question specifies a drug-drug interaction between a PDE5 inhibitor (used for ED/PAH) and a propionic acid derivative NSAID causing gastric inflammation. Drug 3 (Sildenafil) is the PDE5 inhibitor. Drug 2 (Oxaprozin) is the propionic acid NSAID. The interaction triple \"Oxaprozin-gastric inflammation-Sildenafil\" directly links these two drugs as the cause of the adverse effect.  \nANSWER: Sildenafil"}
{"custom_id": "Rofecoxib-Telmisartan-solifenacin_4:upper_bound", "response": "REASON: The drug described has a bicyclic structure with a piperidine ring fused to tetrahydroisoquinoline, linked via an ester to quinuclidine. Solifenacin's SMILES (C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5) matches this structure. The interaction triple states Telmisartan (angiotensin II receptor antagonist with aromatic rings and tetrazole) engages in \u03c0-\u03c0 stacking with solifenacin as the recipient.  \nANSWER: solifenacin"}
{"custom_id": "Carvedilol-Darunavir_0:upper_bound", "response": "REASON: The pharmacokinetic booster (e.g., ritonavir) used with darunavir inhibits CYP3A4, which partially metabolizes carvedilol. Elevated carvedilol levels may exacerbate its alpha-1 antagonism and nonselective beta-blockade, potentially causing severe bronchospasm. Violent coughing from bronchospasm could lead to airway trauma and hemoptysis, aligning with carvedilol's known adverse effect profile (e.g., bronchospasm). Darunavir/ritonavir indirectly increases carvedilol exposure, making carvedilol the proximate cause of the adverse event.  \nANSWER: Carvedilol"}
{"custom_id": "Lidocaine-Pamidronic acid-thiotepa_1:upper_bound", "response": "REASON: The question specifies a nitrogen-containing bisphosphonate (approved since the 1980s for osteoporosis) co-administered with an organophosphorus anti-cancer agent (chemical formula (C2H4N)3PS, brand Tepadina), leading to erythema. From the provided knowledge, Drug 3 (thiotepa) matches the chemical formula and brand name. The interaction triple \"Pamidronic acid-erythema-thiotepa\" directly links the bisphosphonate (Pamidronic acid) and the anti-cancer agent (thiotepa) to the adverse effect (erythema).  \nANSWER: thiotepa"}
{"custom_id": "Loxapine-Histamine H1 receptor_6:upper_bound", "response": "REASON: The question specifies a rhodopsin-like G-protein-coupled receptor linked to histamine effects in smooth muscle, endothelial cells, and the CNS, with activation of phospholipase C signaling. The Histamine H1 receptor matches this description. The tricyclic antipsychotic structurally similar to clozapine and used for schizophrenia is Loxapine, which interacts with and inhibits the Histamine H1 receptor.  \nANSWER: Histamine H1 receptor"}
{"custom_id": "Carvedilol-Darunavir_3:upper_bound", "response": "REASON: Carvedilol contains a hydroxyl group (-OH) in its propanolamine chain (evident from terminal O in SMILES), which can act as a hydrogen bond donor. Darunavir's sulfonamide group (S(=O)(=O)N) contains electronegative oxygen and nitrogen atoms that typically act as hydrogen bond acceptors. The interaction triple explicitly states Carvedilol is the donor.\nANSWER: Carvedilol"}
{"custom_id": "Triazolam-Zaleplon_3:upper_bound", "response": "REASON: The question describes a triazolobenzodiazepine with two chlorinated aromatic rings, matching Triazolam's structure (as per SMILES: two Cl atoms on aromatic rings). The pyrazolopyrimidine derivative with nitrile and N-ethylacetamide matches Zaleplon's structure. The interaction \"Triazolam-\u03c0-\u03c0 Stacking-Zaleplon\" confirms their interaction via aromatic ring stacking.\nANSWER: Triazolam"}
{"custom_id": "Fluorouracil-vincristine_3:upper_bound", "response": "REASON: Fluorouracil contains NH groups (pyrimidine dione structure) that can act as hydrogen bond donors, while vincristine has multiple acceptor groups (carbonyls, methoxy oxygens). The interaction triple explicitly states Fluorouracil donates hydrogen bonds to vincristine.  \nANSWER: Fluorouracil"}
{"custom_id": "Haloperidol-Histamine H1 receptor_6:upper_bound", "response": "REASON: The question specifies a histamine-activated rhodopsin-like GPCR involved in allergic responses that is bound and inhibited by a butyrophenone antipsychotic (haloperidol). The provided interaction triple explicitly states haloperidol binds/inhibits the Histamine H1 receptor, which aligns with the receptor's role in allergies and its GPCR classification.\nANSWER: Histamine H1 receptor"}
{"custom_id": "Naproxen-Norfloxacin_3:upper_bound", "response": "REASON: The interaction triple indicates Naproxen donates a hydrogen bond (subject) to Norfloxacin (object), making Norfloxacin the acceptor. Structurally, Norfloxacin contains a fluorinated quinolone core with a ketone (C=O) and carboxylate group (C(=O)O\u207b at physiological pH, both strong hydrogen bond acceptors. The piperazine nitrogens, if unprotonated, can also act as acceptors. Naproxen\u2019s methoxy group and deprotonated carboxylic acid (COO\u207b) are acceptors, but the triple specifies Naproxen as the donor, implying it provides an H (likely from its unionized carboxylic acid in a specific context). However, under standard conditions, the triple\u2019s direction aligns with Norfloxacin\u2019s acceptor role due to its ketone and carboxylate groups.\nANSWER: Norfloxacin"}
{"custom_id": "Naproxen-alendronic acid-Salmeterol-Beta-1 adrenergic receptor_8:upper_bound", "response": "REASON: The question describes a long-acting asthma/COPD medication administered via dry-powder inhaler (Salmeterol, Drug 3), which interacts with a bisphosphonate (alendronic acid, Drug 2) to cause cholecystitis. The interaction triple for Drug 3 explicitly states \"Salmeterol-binding and activation-Beta-1 adrenergic receptor.\" While Salmeterol is classically a \u03b22 agonist, the provided triples override this convention, and the Beta-1 receptor\u2019s anatomical localization (cardiac tissue, cerebral cortex) matches the question\u2019s specifications.  \nANSWER: Beta-1 adrenergic receptor"}
{"custom_id": "Orphenadrine-Temazepam_3:upper_bound", "response": "REASON: The question specifies the drug with a 1,4-benzodiazepin-2-one core, hydroxyl (-OH), and ketone (C=O) groups. Temazepam's SMILES confirms these features: the benzodiazepinone core (C1=O for the ketone) and a hydroxyl group (O attached to C). Hydrogen bonding involves these groups as donors/acceptors. The interaction triple indicates Orphenadrine forms a hydrogen bond with Temazepam, implying Temazepam's functional groups (hydroxyl/ketone) act as partners.  \nANSWER: Temazepam"}
{"custom_id": "alendronic acid-Indapamide_3:upper_bound", "response": "REASON: Alendronic acid contains multiple hydroxyl (-OH) groups from the phosphonic acid moieties and a primary amine (-NH2), all of which can act as hydrogen bond donors. Indapamide features sulfonamide and chlorobenzamide groups, where the sulfonamide's oxygen atoms and carbonyl groups are hydrogen bond acceptors. The interaction described (alendronic acid as donor) implies alendronic acid's hydroxyl/amine groups donate hydrogen bonds to Indapamide's acceptor sites (e.g., sulfonamide oxygens or amide carbonyl).  \nANSWER: alendronic acid"}
{"custom_id": "Fentanyl-Labetalol-Alpha-1B adrenergic receptor_7:upper_bound", "response": "REASON: The question asks which adrenergic receptor is directly inhibited by the antihypertensive drug (Labetalol) and has a known structure in complex with (+)-cyclazosin. The provided knowledge states that the Alpha-1B adrenergic receptor's structure was determined with (+)-cyclazosin, and Labetalol interacts via \"binding and inhibition\" with this receptor.  \nANSWER: Alpha-1B adrenergic receptor"}
{"custom_id": "Naproxen-Lamotrigine-Zolpidem_1:upper_bound", "response": "REASON: The patient's anticonvulsant (Lamotrigine) interacts with Zolpidem via the triple \"Lamotrigine-Cystitis Interstitial-Zolpidem,\" indicating that combining Lamotrigine with Zolpidem can induce interstitial cystitis. Zolpidem, a short-acting GABA_A receptor enhancer for insomnia, must therefore be avoided.  \nANSWER: Zolpidem"}
{"custom_id": "Lamotrigine-Salmeterol-Beta-3 adrenergic receptor_7:upper_bound", "response": "REASON: The question specifies a long-acting agent for asthma/COPD delivered via dry-powder inhaler, which matches Salmeterol. The provided drug-protein interaction triple explicitly states \"Salmeterol-binding and activation-Beta-3 adrenergic receptor,\" and the ADRB3 gene encodes this receptor. Despite Salmeterol's typical classification as a \u03b22 agonist, the structured data here directly links it to the Beta-3 adrenergic receptor.  \nANSWER: Beta-3 adrenergic receptor"}
{"custom_id": "Lamotrigine-Zaleplon_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided is \"Lamotrigine-apoplexy-Zaleplon,\" structured as subject-predicate-object. This indicates that the interaction between Lamotrigine (the subject) and Zaleplon (the object) is associated with the risk of apoplexy (predicate). The question asks for the agent (the drug causing the risk when interacting with the other), which corresponds to the subject of the triple (Lamotrigine).  \nANSWER: Lamotrigine"}
{"custom_id": "alendronic acid-Alprazolam-Doxazosin-Alpha-1B adrenergic receptor_8:upper_bound", "response": "REASON: The drug described is Doxazosin (Drug 3), used for hypertension, benign prostatic hyperplasia, and PTSD. It is a selective \u03b11-adrenergic blocker. The provided interaction triple explicitly states that Doxazosin interacts with the Alpha-1B adrenergic receptor via \"binding and inhibition.\" Despite clinical knowledge suggesting non-subtype selectivity, the given data directly links Doxazosin to Alpha-1B, making it the answer based on the provided context.  \nANSWER: Alpha-1B adrenergic receptor"}
{"custom_id": "Haloperidol-oxybutynin_0:upper_bound", "response": "REASON: The question specifies a medication antagonizing central D2 receptors (antipsychotic) that may cause apoplexy when combined with an anticholinergic for overactive bladder. Haloperidol (D2 antagonist) and oxybutynin (anticholinergic) are identified via the provided interaction triple, where their combined use is linked to apoplexy.  \nANSWER: Haloperidol"}
{"custom_id": "Carvedilol-Ibuprofen-Midodrine_1:upper_bound", "response": "REASON: The interaction triple provided states that Ibuprofen (NSAID) and Midodrine are associated with \"dry skin.\" Midodrine, an alpha-1 agonist, induces vasoconstriction, which can reduce sweating. Combined with Ibuprofen, this interaction likely exacerbates dry skin. Carvedilol\u2019s interaction with Ibuprofen (cholecystitis) is unrelated to dry skin.  \nANSWER: Midodrine"}
{"custom_id": "Carvedilol-Metolazone-Metoprolol-Alpha-2C adrenergic receptor_8:upper_bound", "response": "REASON: The question describes a cardioselective \u03b21-adrenergic receptor antagonist with CYP2D6-dependent metabolism, adverse effects (insomnia, GI disturbances), and WHO Essential Medicine status. These features align with **Metoprolol** (Drug 3). The query specifies that the drug binds to/inhibits a receptor encoded by **ADRA2C**. The protein interaction triple confirms **Metoprolol** interacts with **Alpha-2C adrenergic receptor**, which is encoded by **ADRA2C**.  \nANSWER: Alpha-2C adrenergic receptor"}
{"custom_id": "Fluorouracil-mitomycin C_3:upper_bound", "response": "REASON: Fluorouracil contains NH groups in its structure (from the amide-like nitrogens in the pyrimidine ring), which can act as hydrogen bond donors. Mitomycin C has multiple oxygen-based groups (e.g., methoxy, carbonyl), which are hydrogen bond acceptors. The interaction triple explicitly states Fluorouracil is the donor.  \nANSWER: Fluorouracil"}
{"custom_id": "Ziprasidone-Desloratadine_0:upper_bound", "response": "REASON: Ziprasidone, as an atypical antipsychotic, has a known side effect profile that includes QT interval prolongation, which can lead to arrhythmias such as tachycardia. Additionally, antipsychotics like ziprasidone may cause autonomic effects (e.g., orthostatic hypotension), triggering reflex tachycardia. Desloratadine, a second-generation antihistamine, has minimal cardiac effects compared to first-generation antihistamines and is not strongly associated with heart rate increases. The drug-drug interaction triple provided explicitly links ziprasidone to increased heart rate in the presence of desloratadine, suggesting ziprasidone\u2019s cardiac effects are amplified or more clinically significant in this combination.\n\nANSWER: Ziprasidone"}
{"custom_id": "alendronic acid-Lamivudine-Metoprolol-Perphenazine_5:upper_bound", "response": "REASON: The question describes a drug with a piperazine ring attached to a chlorinated tricyclic phenothiazine core (matching Perphenazine's structure based on its SMILES) and a beta-blocker with a para-substituted phenyl ether and isopropylamino ethanol side chain (matching Metoprolol's SMILES). The interaction triple \"Metoprolol-Hydrogen Bonding-Perphenazine\" confirms the interaction.  \nANSWER: Perphenazine"}
{"custom_id": "Cimetidine-Citalopram-nevirapine-oxybutynin_2:upper_bound", "response": "REASON: The question involves identifying a drug (anticholinergic for overactive bladder) that interacts with a non-nucleoside reverse transcriptase inhibitor (nevirapine) to cause emesis. The provided interaction triple explicitly states **nevirapine-emesis-oxybutynin**, linking nevirapine (HIV therapy drug) and oxybutynin (anticholinergic) to emesis. Oxybutynin's background information confirms its anticholinergic role and adverse effects (xerostomia, urinary retention), aligning with the question's context.  \nANSWER: oxybutynin"}
{"custom_id": "Celecoxib-Midodrine_3:upper_bound", "response": "REASON: Celecoxib contains a sulfonamide group (-S(=O)\u2082NH-), which has both hydrogen bond donor (NH) and acceptor (O) capabilities. Midodrine has a primary amine (-NH\u2082), amide (-CONH-), and hydroxyl (-OH) groups, all of which can act as hydrogen bond donors or acceptors. The sulfonamide NH in Celecoxib can donate hydrogen bonds to Midodrine\u2019s amide carbonyl oxygen or hydroxyl oxygen, while the sulfonamide oxygen atoms can accept hydrogen bonds from Midodrine\u2019s amine or amide NH groups. This mutual compatibility enables Celecoxib to form hydrogen bonds with Midodrine.  \nANSWER: Celecoxib"}
{"custom_id": "Metronidazole-Fosphenytoin_3:upper_bound", "response": "REASON: Metronidazole contains a hydroxyethyl group (-OH) as part of its structure, which can act as a hydrogen bond donor. Fosphenytoin has multiple hydrogen bond acceptors, including carbonyl oxygens in its hydantoin core and phosphate oxygens. The interaction involves Metronidazole donating a hydrogen bond to an acceptor group in Fosphenytoin.  \nANSWER: Metronidazole"}
{"custom_id": "Lamotrigine-Oxaprozin_3:upper_bound", "response": "REASON: Lamotrigine contains amino groups (-NH2) that act as hydrogen bond donors. Oxaprozin contains a deprotonated carboxylic acid group (-COO\u207b) at physiological pH, which serves as a strong hydrogen bond acceptor. Additionally, the carbonyl oxygen (C=O) and oxazole oxygen in Oxaprozin can also accept hydrogen bonds. The interaction described (Lamotrigine-Hydrogen Bond-Oxaprozin) indicates that Lamotrigine donates a hydrogen bond to Oxaprozin, making Oxaprozin the acceptor.  \nANSWER: Oxaprozin"}
{"custom_id": "Candesartan-Perindopril_3:upper_bound", "response": "REASON: Candesartan contains a tetrazole ring (N5=NNN=N5), which has multiple electron-rich nitrogen atoms capable of acting as hydrogen bond acceptors. Perindopril's perhydroindole core has a secondary amine (NH) that acts as a hydrogen bond donor, and its amide nitrogen (C(=O)N) has reduced electron density due to resonance with the carbonyl group. The tetrazole's aromatic nitrogen atoms are more electron-rich than Perindopril's nitrogens, making Candesartan the hydrogen bond acceptor.\nANSWER: Candesartan"}
{"custom_id": "Bumetanide-Ranolazine_3:upper_bound", "response": "REASON: Bumetanide contains a sulfonamide group (S(=O)(=O)N) with an NH donor and oxygen acceptors, along with a carboxylic acid (-COOH) that can donate protons. Ranolazine has carbonyl (C=O), ether (O), and hydroxyl (-OH) groups, which are hydrogen bond acceptors. The documented interaction (Bumetanide-Hydrogen Bonding-Ranolazine) implies Bumetanide's NH or OH groups act as donors, bonding with Ranolazine's acceptors (e.g., carbonyl or ether oxygens). \nANSWER: Bumetanide"}
{"custom_id": "Methylphenidate-Ofloxacin-Imatinib_4:upper_bound", "response": "REASON: The compound must contain both a piperazine ring and a fused pyrimidine-phenyl structure. Drug 3 (Imatinib) includes a piperazine ring (from \"CN3CCN(CC3)C\" in its SMILES) and a pyrimidine ring (\"NC4=NC=CC(=N4)\"). While the pyrimidine is not explicitly fused to a phenyl ring in the SMILES, Imatinib's known structure includes a pyrimidine adjacent to aromatic systems. The hydrogen bond interaction involves Ofloxacin (a fluoroquinolone with a fluorinated aromatic system and a piperazine substituent, though morpholine is absent, suggesting a possible discrepancy in the question's description). Imatinib interacts with Ofloxacin via hydrogen bonding, aligning with the interaction triple. \n\nANSWER: Imatinib"}
{"custom_id": "Rofecoxib-Triazolam_0:upper_bound", "response": "REASON: The question asks for the drug associated with cholecystitis when interacting with a triazolobenzodiazepine (specifically Triazolam, used for severe insomnia). The provided DRUG-DRUG INTERACTION TRIPLE explicitly states \"Rofecoxib-cholecystitis-Triazolam,\" indicating Rofecoxib as the interacting drug linked to this adverse effect. Triazolam is the CNS depressant triazolobenzodiazepine in the interaction, and cholecystitis is the adverse outcome attributed to Rofecoxib in this context.  \nANSWER: Rofecoxib"}
{"custom_id": "Celecoxib-Labetalol_3:upper_bound", "response": "REASON: Celecoxib contains a sulfonamide group (-SO\u2082NH-) where the NH can act as a hydrogen bond donor. Labetalol has a hydroxybenzamide group with a carbonyl oxygen (C=O), which is a hydrogen bond acceptor. The triple \"Celecoxib-Hydrogen Bonding-Labetalol\" implies Celecoxib donates a hydrogen bond (via sulfonamide NH) to Labetalol's acceptor (carbonyl oxygen).  \nANSWER: Celecoxib"}
{"custom_id": "indometacin-oxybutynin_3:upper_bound", "response": "REASON: The hydrogen bond donor is determined by the presence of a hydrogen atom attached to an electronegative atom (e.g., O or N). Indometacin contains an amide NH group (H-bond donor) and a carboxylic acid (-COOH, protonated at lower pH), both of which can donate hydrogen bonds. Oxybutynin has a tertiary alcohol (-OH, donor) and an ester carbonyl (acceptor). The provided interaction triple (indometacin-Hydrogen Bonding-oxybutynin) implies indometacin acts as the donor, likely via its amide NH or carboxylic acid group, interacting with oxybutynin's ester carbonyl oxygen (acceptor).  \nANSWER: indometacin"}
{"custom_id": "Famotidine-Pirbuterol_0:upper_bound", "response": "REASON: The question asks for the medication associated with elevated cholesterol risk when combined with a short-acting \u03b22 agonist (Pirbuterol). The interaction triple explicitly states \"Famotidine-elevated cholesterol-Pirbuterol,\" indicating Famotidine is the drug linked to this interaction when used alongside Pirbuterol.\nANSWER: Famotidine"}
{"custom_id": "Ranitidine-Sibutramine-Zolpidem-vincristine_5:upper_bound", "response": "REASON: The question describes a drug with a highly complex polycyclic structure (multiple fused rings and ester groups) that experiences steric clashes with a compound containing a substituted imidazopyridine core and N,N-dimethylacetamide. Analyzing the SMILES and interaction triples: Zolpidem (Drug 3) has an imidazopyridine core (evident in its SMILES) and an N,N-dimethylacetamide group. The interaction triple \"Zolpidem-Steric Clashes-vincristine\" indicates that Zolpidem clashes with vincristine. Vincristine (Drug 4) has a highly complex polycyclic structure (evident in its long SMILES with fused rings and ester groups, typical of vinca alkaloids). Thus, vincristine is the polycyclic drug clashing with Zolpidem\u2019s imidazopyridine-containing structure.\n\nANSWER: vincristine"}
{"custom_id": "Fentanyl-Ketorolac-oxybutynin-Zaleplon_5:upper_bound", "response": "REASON: The question describes a drug with a pyrazolopyrimidine core containing a cyano group (C#N), methyl group, and N-ethylacetamide moiety. Zaleplon (DRUG 4) matches this structure based on its SMILES: the pyrazolopyrimidine core (C=NN23 in the fused ring system), cyano group (C#N), and N-ethylacetamide (CCN(C(=O)C)). The interaction triple states oxybutynin (tertiary amine-containing ether-substituted cyclohexylbenzene) engages in **Pi-Pi Stacking** with Zaleplon, aligning with the question's query.  \nANSWER: Zaleplon"}
{"custom_id": "Labetalol-Metoprolol-Perphenazine-Alpha-2A adrenergic receptor_8:upper_bound", "response": "REASON: The question specifies a medium-potency antipsychotic (10\u00d7 potency of chlorpromazine at D2 receptors) originally marketed as Trilafon, which is **Perphenazine**. Per the interaction triples, Perphenazine directly inhibits the **Alpha-2A adrenergic receptor** via \"binding and inhibition.\" The drug-drug interaction involves Metoprolol (\u03b21-adrenergic antagonist for hypertension/migraine), as noted in the **Metoprolol-insulin dependent diabetes mellitus-Perphenazine** triple.  \nANSWER: Alpha-2A adrenergic receptor"}
{"custom_id": "alendronic acid-Efavirenz-Lamivudine-Metoprolol_2:upper_bound", "response": "REASON: The question describes a patient on a nucleoside reverse transcriptase inhibitor (NRTI) for hepatitis B/HIV (Lamivudine, which causes lactic acidosis and GI issues) developing dysarthria when co-administered with a cardioselective \u03b21-blocker metabolized by CYP2D6. Metoprolol is a cardioselective \u03b21-blocker used for the listed conditions and exhibits CYP2D6-dependent metabolism. The interaction triple explicitly states \"Lamivudine-dysarthria-Metoprolol,\" confirming the link.  \nANSWER: Metoprolol"}
{"custom_id": "Amlodipine-Rosiglitazone_0:upper_bound", "response": "REASON: The interaction triple states Amlodipine is associated with apoplexy when combined with Rosiglitazone (a thiazolidinedione-class PPAR\u03b3 agonist used for Type 2 diabetes). The question asks for the drug interacting with the PPAR\u03b3 agonist (Rosiglitazone) to increase apoplexy risk, which matches the triple's subject (Amlodipine).  \nANSWER: Amlodipine"}
{"custom_id": "Fentanyl-Labetalol-Metoprolol-Pirbuterol_2:upper_bound", "response": "REASON: The question involves a \u03b21-blocker (Metoprolol) and a short-acting \u03b22 agonist (Pirbuterol). The interaction triple \"Metoprolol-erythema-Pirbuterol\" directly links erythema to their combined use. While \u03b21-selective blockers minimize \u03b22 antagonism, residual \u03b22-blockade could reduce Pirbuterol's vasodilatory effects, potentially unopposing \u03b1-mediated vasoconstriction or causing paradoxical vascular responses, leading to erythema. The provided interaction data explicitly identifies Pirbuterol as the drug contributing to erythema with Metoprolol.  \nANSWER: Pirbuterol"}
{"custom_id": "Bumetanide-Fenofibrate_0:upper_bound", "response": "REASON: The question involves identifying which therapy increases hepatic neoplasia risk when combined. Fenofibrate, a PPAR\u03b1 agonist, is known for potential hepatotoxicity and peroxisome proliferation linked to hepatic neoplasia in preclinical models. The provided drug-drug interaction triple explicitly links Bumetanide and Fenofibrate to hepatic neoplasia, with Fenofibrate's PPAR\u03b1 agonism being the mechanism implicated in this risk.  \nANSWER: Fenofibrate"}
{"custom_id": "Famotidine-Pilocarpine_3:upper_bound", "response": "REASON: Famotidine contains sulfonamide and amidino groups, which can act as hydrogen bond donors (e.g., NH in sulfonamide or protonated amidino groups). Pilocarpine has a ketone oxygen in its dihydrofuranone ring, a strong hydrogen bond acceptor. Since the interaction triple specifies Famotidine (subject) hydrogen bonding with Pilocarpine (object), Famotidine likely donates a hydrogen (donor), while Pilocarpine's ketone oxygen accepts it (acceptor).  \nANSWER: Pilocarpine"}
{"custom_id": "Fentanyl-Loxapine-Alpha-2C adrenergic receptor_7:upper_bound", "response": "REASON: The question specifies an antipsychotic (Loxapine) that metabolizes into a tricyclic antidepressant (Amoxapine) and interacts with Fentanyl (a high \u03bc-opioid receptor affinity synthetic opioid) to cause deglutition disorder. The drug-protein interaction triple explicitly states that Loxapine binds and inhibits the Alpha-2C adrenergic receptor.  \nANSWER: Alpha-2C adrenergic receptor"}
{"custom_id": "Naproxen-Zolpidem_0:upper_bound", "response": "REASON: The question specifies a nonbenzodiazepine hypnotic (Zolpidem) interacting with a prostaglandin-inhibiting NSAID (Naproxen) in the context of adenomyosis. The provided interaction triple explicitly links Naproxen and Zolpidem via adenomyosis, confirming Zolpidem as the medication in question.\nANSWER: Zolpidem"}
{"custom_id": "Furosemide-vincristine_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided explicitly states \"Furosemide-amyloidosis-vincristine,\" indicating that co-administration of furosemide and vincristine is associated with amyloidosis. In interaction triples (subject-predicate-object), the subject (furosemide) is linked to the object (vincristine) via the predicate (amyloidosis). This implies that furosemide has been reported in literature to interact with vincristine in the context of amyloidosis. While neither drug's background information directly mentions amyloidosis, the interaction triple specifies this relationship.  \nANSWER: Furosemide"}
{"custom_id": "Ketorolac-Duloxetine_0:upper_bound", "response": "REASON: The question asks for a medication that inhibits prostaglandin synthesis (indicative of NSAIDs like ketorolac) and is less effective for neuropathic pain compared to an SNRI (duloxetine). Ketorolac, an NSAID, is primarily used for nociceptive pain (e.g., acute inflammatory pain) via COX inhibition, while duloxetine, an SNRI, modulates neurotransmitters to address neuropathic pain and central sensitization. Neuropathic pain (e.g., from back injury) involves nerve dysfunction, which NSAIDs like ketorolac are not indicated for, unlike SNRIs like duloxetine.  \nANSWER: Ketorolac"}
{"custom_id": "Furosemide-hydralazine_3:upper_bound", "response": "REASON: Furosemide contains sulfonamide (-SO\u2082NH) and carboxyl (-COOH) groups, which can act as hydrogen bond donors (via -NH and -OH). Hydralazine's phthalazine core has aromatic nitrogen atoms with lone pairs capable of accepting hydrogen bonds. The interaction described (Furosemide as donor, hydralazine as acceptor) aligns with these structural features.\nANSWER: hydralazine"}
{"custom_id": "Diazepam-Desloratadine_3:upper_bound", "response": "REASON: In \u03c0-\u03c0 stacking interactions, the \u03c0-acceptor typically has an electron-deficient aromatic system. Diazepam contains a chlorinated benzene ring (electron-withdrawing Cl reduces electron density) and a diazepine ring. Desloratadine features a pyridine ring (inherently electron-deficient due to the electronegative nitrogen in the aromatic system) and a chlorinated benzene. Pyridine's electron deficiency exceeds that of chlorobenzene, making Desloratadine's pyridine ring the stronger \u03c0-acceptor. The interaction triple (Diazepam-\u03c0-\u03c0 Stacking-Desloratadine) aligns with Diazepam's phenyl group (relatively electron-rich) acting as the donor and Desloratadine's pyridine as the acceptor.  \nANSWER: Desloratadine"}
{"custom_id": "Haloperidol-indometacin-vincristine-Torasemide_5:upper_bound", "response": "REASON: The question describes a drug with a phenylamino-pyridine core, sulfonamide linker, and acylguanidine group. Torasemide (DRUG 4) matches this structural profile: its SMILES includes a pyridine ring (C=NC=C2), a sulfonamide group (S(=O)(=O)N), and a urea-like moiety (NC(=O)NC(C)C), which may correspond to the acylguanidine. The interaction triples state that vincristine (a multi-ringed indole-based anticancer agent) forms a hydrogen bond with Torasemide, aligning with the query's requirement.  \nANSWER: Torasemide"}
{"custom_id": "Theophylline-Bumetanide-vincristine-Torasemide_5:upper_bound", "response": "REASON: The drug in question must have a methylated aniline (methyl-substituted benzene with an amino group derivative) and a sulfonylurea group fused to a pyridine. Torasemide (Drug4) matches this: its SMILES shows a methylated benzene (CC1=CC...) connected via NH to a pyridine ring (C=NC=C2), with a sulfonylurea group (S(=O)(=O)NC(=O)NC(C)C). The interaction triple lists vincristine (alkaloid) hydrogen bonding with Torasemide, aligning with the question's context of the alkaloid interacting with the sulfonamide-containing diuretic (Torasemide itself). Though the interaction direction in the triple suggests vincristine is the subject, structural alignment prioritizes Torasemide as the answer.  \nANSWER: Torasemide"}
{"custom_id": "Naproxen-Carvedilol_0:upper_bound", "response": "REASON: The question specifies a nonselective beta-adrenergic blocker with alpha-1 receptor antagonism used for heart failure and hypertension. Carvedilol matches this description. The interaction with an NSAID (Naproxen), which inhibits COX enzymes, is explicitly stated in the Drug-Drug Interaction Triple as causing adenopathy. Carvedilol is the drug associated with this adverse effect in the interaction context.  \nANSWER: Carvedilol"}
{"custom_id": "Diazepam-Temozolomide-Thalidomide_4:upper_bound", "response": "REASON: The question describes a compound with a glutarimide ring fused to a phthalimide moiety, which matches Thalidomide's structure (DRUG 3). The triazene-bearing imidazotetrazine is Temozolomide (DRUG 2), which interacts via hydrogen bonding with Thalidomide (as per DRUG 2-DRUG 3 interaction triple). Additionally, Temozolomide accepts a hydrogen bond from Diazepam (DRUG 1, a benzodiazepine with a chlorinated aromatic ring), aligning with the DRUG 1-DRUG 2 interaction triple. \n\nANSWER: Thalidomide"}
{"custom_id": "alendronic acid-Imatinib_3:upper_bound", "response": "REASON: Hydrogen bond acceptors require electronegative atoms with lone pairs. Imatinib's structure contains an amide carbonyl oxygen and tertiary amines in the piperazine moiety, both of which act as acceptors. Alendronic acid has phosphonic acid hydroxyls (donors) and a protonated primary amine (donor at physiological pH). The interaction triple explicitly states alendronic acid donates the hydrogen bond to Imatinib, confirming Imatinib as the acceptor.\nANSWER: Imatinib"}
{"custom_id": "Risedronic acid-Trazodone-Alpha-2C adrenergic receptor_7:upper_bound", "response": "REASON: The question specifies a sedating antidepressant that is a serotonin antagonist and reuptake inhibitor (SARI) interacting with a receptor encoded by the **ADRA2C** gene. **Trazodone** is identified as the SARI in the interaction. The **ADRA2C** gene encodes the **alpha-2C adrenergic receptor**, and the provided triple confirms Trazodone binds and inhibits this receptor.\nANSWER: Alpha-2C adrenergic receptor"}
{"custom_id": "Rofecoxib-Zolpidem-vincristine-Torasemide_2:upper_bound", "response": "REASON: The question describes a drug-drug interaction between a vinca alkaloid (vincristine, used for leukemia/neuroblastoma) and a sulfonamide-class loop diuretic (among top 200 US prescriptions in 2022). The interaction triple for vincristine-drug toxicity-Torasemide directly links vincristine toxicity to Torasemide. Torasemide is explicitly noted as a sulfonamide loop diuretic used for heart failure/kidney disease and ranked 184th in US prescriptions in 2022, fulfilling all criteria.  \nANSWER: Torasemide"}
{"custom_id": "Candesartan-Fenofibrate-Modafinil-Bimatoprost_2:upper_bound", "response": "REASON: The question specifies an ophthalmic prostaglandin analog causing nocturia when interacting with a CNS stimulant (Modafinil). The interaction triple Modafinil-nocturia-Bimatoprost directly links these two drugs, with Bimatoprost being the prostaglandin analog described to cause eye color changes and used as eye drops.  \nANSWER: Bimatoprost"}
{"custom_id": "Diazepam-Ofloxacin_0:upper_bound", "response": "REASON: The drug-drug interaction triple explicitly states \"Diazepam-gastric inflammation-Ofloxacin,\" indicating that when Diazepam (a benzodiazepine) is administered with Ofloxacin (a fluoroquinolone), gastric inflammation is associated. The predicate structure implies the interaction effect (gastric inflammation) arises from the combination, but the question specifies which drug is linked to causing the effect when paired with the other. Since the triple positions Diazepam as the subject and Ofloxacin as the object, this suggests Diazepam is the agent associated with inducing gastric inflammation when co-administered with Ofloxacin.  \nANSWER: Diazepam"}
{"custom_id": "Pamidronic acid-thiotepa_3:upper_bound", "response": "REASON: Pamidronic acid contains hydroxyl groups (-OH) from its phosphonic acid groups and tertiary alcohol, which can act as hydrogen bond donors. Thiotepa lacks hydroxyl groups or other proton-donating groups, as its aziridine nitrogens are not bonded to hydrogen atoms and its phosphorothioate core (P=S) cannot donate hydrogen bonds.  \nANSWER: Pamidronic acid"}
{"custom_id": "Cimetidine-Labetalol-Metoprolol-Prostacyclin receptor_8:upper_bound", "response": "REASON: The question describes a cardioselective drug used for hypertension and angina with metabolism dependent on CYP2D6 (cytochrome P450 2D6), which aligns with **Metoprolol** (\u03b21-selective antagonist). The receptor in question mediates vasodilation and is clinically relevant in pathological vasoconstriction. The **Prostacyclin receptor** (IP receptor) matches this description, and the interaction triple explicitly states that Metoprolol binds to and activates this receptor.  \nANSWER: Prostacyclin receptor"}
{"custom_id": "Naproxen-Furosemide-Zolpidem-vincristine_5:upper_bound", "response": "REASON: The question describes a drug with a multi-ring indole-based scaffold (matching **vincristine**'s structure) experiencing steric clashes with a molecule containing an imidazo[1,2-a]pyridine core substituted with a tolyl group and methylamide (matching **Zolpidem**). The provided interaction triple explicitly states **Zolpidem-Steric Clashes-vincristine**, confirming vincristine as the drug experiencing steric clashes.  \nANSWER: vincristine"}
{"custom_id": "Fentanyl-vincristine_3:upper_bound", "response": "REASON: The interaction triple states Fentanyl causes a steric clash with vincristine. Vincristine's SMILES reveals a large, complex structure with multiple fused rings, methoxycarbonyl groups, and indole motifs, which are bulky and prone to steric hindrance. Fentanyl's smaller, less bulky structure (piperidine, phenethyl, anilide) is more likely to cause spatial interference with vincristine's intricate 3D arrangement.\nANSWER: vincristine"}
{"custom_id": "Diazepam-Temozolomide_3:upper_bound", "response": "REASON: Hydrogen bond donors require a hydrogen atom bonded to an electronegative atom (e.g., N-H or O-H). Diazepam lacks such groups: its nitrogens are tertiary (N-CH\u2083) or part of imine (C=N) groups, which cannot donate hydrogen. Temozolomide contains an amide group (C(=O)N-H) in its imidazotetrazine ring, providing an N-H group capable of acting as a hydrogen bond donor.  \nANSWER: Temozolomide"}
{"custom_id": "Efavirenz-Lamivudine_0:upper_bound", "response": "REASON: The question asks for the antiretroviral contraindicated in pregnancy (due to teratogenicity) that causes gastric inflammation when combined with its nucleoside counterpart (safe in pregnancy). Efavirenz (NNRTI) is explicitly contraindicated in pregnancy, while Lamivudine (NRTI) is safe. The drug-drug interaction triple directly links Efavirenz to gastric inflammation when interacting with Lamivudine, fulfilling the query's criteria.  \nANSWER: Efavirenz"}
{"custom_id": "Aciclovir-Azelastine_0:upper_bound", "response": "REASON: The drug-drug interaction triple specifies Aciclovir as the subject associated with erythema when interacting with Azelastine (object). Aciclovir's profile includes nephrotoxicity and gastrointestinal adverse effects, but erythema is not listed as a standalone side effect. However, the interaction with Azelastine explicitly links Aciclovir to erythema. Azelastine\u2019s adverse effects (e.g., dysgeusia, somnolence) do not include erythema. Thus, the interaction implies Aciclovir is the drug tied to erythema in this scenario.\nANSWER: Aciclovir"}
{"custom_id": "indometacin-Terazosin_0:upper_bound", "response": "REASON: The drug-drug interaction triple indicates that indometacin is associated with erythema when interacting with Terazosin. Terazosin is the alpha-1 blocker in the scenario, so the medication causing erythema as a result of concomitant use is indometacin.\nANSWER: indometacin"}
{"custom_id": "Ofloxacin-Darunavir_3:upper_bound", "response": "REASON: The question describes Drug 1 (Ofloxacin) with a bicyclic ring fused to a piperazine, fluorine, and ketone groups, and Drug 2 (Darunavir) with sulfonamide-linked phenyl and cyclic ether moieties. The provided interaction triple explicitly states **Ofloxacin-Hydrogen Bonding-Darunavir**, confirming Ofloxacin as the subject engaging in hydrogen bonding with Darunavir. Hydrogen bonding likely occurs between Ofloxacin's ketone/amine groups (hydrogen donors/acceptors) and Darunavir's sulfonamide/ether oxygens (hydrogen acceptors).  \nANSWER: Ofloxacin"}
{"custom_id": "Fentanyl-Labetalol_0:upper_bound", "response": "REASON: The question asks for the drug used for severe pain via \u03bc-opioid receptor activation in a back injury scenario, contrasting it with a blood pressure drug (adrenergic blocker). Fentanyl is explicitly described as a potent \u03bc-opioid agonist for severe pain, while Labetalol is an adrenergic receptor antagonist for hypertension. The task requires selecting the pain-management drug over the blood pressure medication.  \nANSWER: Fentanyl"}
{"custom_id": "indometacin-Sildenafil_0:upper_bound", "response": "REASON: The question specifies a selective PDE5 inhibitor associated with apoplexy when interacting with an NSAID (indometacin). Sildenafil is a PDE5 inhibitor that enhances nitric oxide-mediated vasodilation. NSAIDs like indometacin inhibit prostaglandin synthesis, which may counteract vasodilatory effects or exacerbate vascular risks. The provided interaction triple explicitly links indometacin, apoplexy, and Sildenafil.  \nANSWER: Sildenafil"}
{"custom_id": "Citalopram-Propofol_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided explicitly states \"Citalopram-cataract-Propofol,\" indicating that co-administration of these two agents is associated with cataract development. Since the question specifies identifying the implicated drug (as opposed to the combination), the subject of the triple (Citalopram) is framed as the agent linked to this adverse effect when interacting with Propofol.  \nANSWER: Citalopram"}
{"custom_id": "Triazolam-Rosiglitazone-Bimatoprost_4:upper_bound", "response": "REASON: The question describes a drug with a cyclopentane fused to a hydroxylated alkyl chain terminating in an amide, phenyl, and alkene substituents. Bimatoprost (DRUG 3) matches this structure based on its SMILES, which includes a cyclopentane ring, hydroxyl groups, an amide group (CCNC(=O)), phenyl (CCC2=CC=CC=C2), and alkene (CCCC=CC). The interaction triples confirm Rosiglitazone (thiazolidinedione with pyridyl group) forms a hydrogen bond with Bimatoprost, while Rosiglitazone also \u03c0-\u03c0 stacks with Triazolam (dichlorinated triazolobenzodiazepine).  \nANSWER: Bimatoprost"}
{"custom_id": "Naproxen-Gabapentin_0:upper_bound", "response": "REASON: The question asks for the medication associated with increased gastric inflammation risk due to non-selective COX inhibition when combined with a neuropathic pain drug targeting the \u03b12\u03b4-1 subunit (Gabapentin). Naproxen is an NSAID that non-selectively inhibits COX-1 and COX-2, reducing gastroprotective prostaglandins and increasing gastrointestinal toxicity. Gabapentin binds the \u03b12\u03b4-1 subunit but does not directly cause gastric inflammation. The provided interaction triple explicitly links Naproxen to gastric inflammation when combined with Gabapentin.\nANSWER: Naproxen"}
{"custom_id": "Duloxetine-Desloratadine_3:upper_bound", "response": "REASON: Duloxetine contains a thiophene ring (electron-rich due to sulfur's conjugated lone pairs) and a naphthalene system, which are \u03c0-electron donors. Desloratadine has a chlorinated aromatic ring (electron-deficient due to chlorine's electron-withdrawing effect), acting as the acceptor. The interaction triple explicitly states Duloxetine as the \u03c0-\u03c0 stacking donor.  \nANSWER: Duloxetine"}
{"custom_id": "Loxapine-Muscarinic acetylcholine receptor M4_6:upper_bound", "response": "REASON: The question asks for the protein encoded by CHRM4 that is inhibited by a tricyclic antipsychotic structurally similar to clozapine. The CHRM4 gene encodes the **Muscarinic acetylcholine receptor M4**, and the drug **Loxapine** (a tricyclic antipsychotic structurally related to clozapine) binds and inhibits this receptor, as per the provided interaction triple.  \nANSWER: Muscarinic acetylcholine receptor M4"}
{"custom_id": "indometacin-vincristine-Torasemide_1:upper_bound", "response": "REASON: The interaction triple between vincristine (Drug 2) and Torasemide (Drug 3) explicitly states \"vincristine-drug toxicity NOS-Torasemide,\" indicating that co-administration of these two drugs leads to unspecified drug toxicity. The question specifies a mitotic inhibitor (vinca alkaloid, i.e., vincristine) and a sulfonamide loop diuretic (Torasemide) causing this interaction.  \nANSWER: Torasemide"}
{"custom_id": "Cimetidine-Duloxetine_3:upper_bound", "response": "REASON: The question specifies a drug with an imidazole ring substituted with sulfur and cyano groups, which matches **Cimetidine** (DRUG 1 SMILES includes an imidazole ring (N=CN1), sulfur (S), and cyano (NC#N). The molecule with a thiophene ring and ether linkage is **Duloxetine** (DRUG 2 SMILES includes C1=CC=CS1 for thiophene and OC2 for ether). Hydrogen bonding is feasible between Cimetidine's imidazole (N\u2013H donor) or cyano (C\u2261N acceptor) and Duloxetine's ether oxygen (O acceptor), aligning with the interaction triple provided.  \nANSWER: Cimetidine"}
{"custom_id": "Amlodipine-Metolazone-Metoprolol-Gastrin-releasing peptide receptor_8:upper_bound", "response": "REASON: The question asks for a protein highly expressed in the pancreas, involved in gastrointestinal hormone release and smooth muscle contraction, directly bound and activated by a cardioselective \u03b21-adrenergic antagonist (Metoprolol, Drug 3). The **DRUG 3 - PROTEIN INTERACTION TRIPLE** explicitly states that Metoprolol binds and activates the **Gastrin-releasing peptide receptor (GRPR)**. The **PROTEIN BACKGROUND INFORMATION** confirms GRPR's pancreatic expression, role in hormone release, and smooth muscle function, aligning with the question's criteria. The co-prescribed diuretic is Metolazone (Drug 2), a thiazide-like agent with dehydration risks when combined with loop diuretics.  \nANSWER: Gastrin-releasing peptide receptor"}
{"custom_id": "Gabapentin-Ibuprofen_0:upper_bound", "response": "REASON: The question specifies a medication that modulates voltage-gated calcium channels (Gabapentin) and a cyclooxygenase inhibitor (Ibuprofen). The drug-drug interaction triple explicitly links Gabapentin and Ibuprofen to erythema as an adverse effect. Gabapentin is the medication characterized by calcium channel modulation, making it the subject of the interaction.  \nANSWER: Gabapentin"}
{"custom_id": "Furosemide-Salmeterol_3:upper_bound", "response": "REASON: Furosemide contains both sulfonamide (NH) and carboxylic acid (OH) groups, which are strong hydrogen bond donors. Salmeterol has ether oxygens (hydrogen bond acceptors) in its aliphatic chain. The interaction triple specifies Furosemide as the donor, implying its NH or OH groups donate hydrogen bonds to Salmeterol's ether oxygen acceptors.  \nANSWER: Furosemide"}
{"custom_id": "Amlodipine-Sufentanil_0:upper_bound", "response": "REASON: The drug-drug interaction triple indicates that co-administration of Amlodipine (a dihydropyridine calcium channel blocker) and Sufentanil (ultra-potent synthetic opioid) increases the risk of right heart failure. Amlodipine induces vasodilation, reducing systemic vascular resistance, while Sufentanil\u2019s potent opioid effects may exacerbate hypotension and impair cardiac output. This combination could synergistically compromise venous return and right ventricular function, particularly in susceptible patients with pre-existing cardiovascular compromise.\n\nANSWER: Sufentanil"}
{"custom_id": "Fentanyl-Trimethoprim_0:upper_bound", "response": "REASON: The question specifies a medication that blocks bacterial folate metabolism (trimethoprim, which inhibits dihydrofolate reductase) and is used for bladder/ear infections. The interaction with fentanyl (a potent opioid) is linked to dysarthria, as per the provided drug-drug interaction triple.\nANSWER: Trimethoprim"}
{"custom_id": "Tolbutamide-Perindopril_0:upper_bound", "response": "REASON: The question specifies a medication that inhibits angiotensin II synthesis (ACE inhibitor) causing muscle disorders when combined with a first-generation sulfonylurea (tolbutamide). The provided interaction triple directly links tolbutamide and perindopril to muscle disorders. Perindopril is the ACE inhibitor in the context.\nANSWER: Perindopril"}
{"custom_id": "Naproxen-Lamotrigine_3:upper_bound", "response": "REASON: Naproxen contains a carboxylic acid group (-COOH), where the hydroxyl (-OH) can act as a hydrogen bond donor. Lamotrigine's triazine ring nitrogens and amine groups are potential hydrogen bond acceptors but not donors in this interaction. The provided triple specifies Naproxen as the donor in the hydrogen bonding interaction with Lamotrigine.  \nANSWER: Naproxen"}
{"custom_id": "Ibuprofen-desvenlafaxine_3:upper_bound", "response": "REASON: The hydrogen bond acceptor is typically an atom with lone electron pairs, such as oxygen or nitrogen. Ibuprofen contains a carboxylic acid group (-COOH), where the carbonyl oxygen is a potential acceptor, but the acidic -OH acts primarily as a donor. Desvenlafaxine features a dimethylamino group (-N(CH\u2083)\u2082), a tertiary amine with lone pairs on nitrogen, making it a strong hydrogen bond acceptor. Additionally, desvenlafaxine's phenol and cyclohexanol -OH groups are donors, not acceptors. In an interaction, ibuprofen's -OH (donor) would likely form a hydrogen bond with desvenlafaxine's dimethylamino group (acceptor).\nANSWER: desvenlafaxine"}
{"custom_id": "Candesartan-Citalopram_3:upper_bound", "response": "REASON: The drug interaction triple specifies Candesartan as the subject engaging in \u03c0-\u03c0 stacking with Citalopram. Candesartan's biphenyl-tetrazole moiety contains aromatic systems (biphenyl rings) capable of \u03c0-\u03c0 interactions, while Citalopram's phthalane ring and fluorophenyl group also have aromaticity. The triple explicitly assigns Candesartan as the \u03c0-\u03c0 stacking partner acting on Citalopram.  \nANSWER: Candesartan"}
{"custom_id": "Amlodipine-Exemestane_0:upper_bound", "response": "REASON: The question asks for an antihypertensive calcium channel blocker linked to pain when combined with an aromatase inhibitor (Exemestane) used in hormone-receptor-positive breast cancer. The provided interaction triple explicitly states that Amlodipine (a calcium channel blocker) is associated with pain when used with Exemestane (an aromatase inhibitor). Amlodipine's role as a globally recognized antihypertensive aligns with the query's requirements.\nANSWER: Amlodipine"}
{"custom_id": "Ofloxacin-Imatinib_3:upper_bound", "response": "REASON: The question describes two drugs based on their structural features. Ofloxacin (Drug 1) contains a piperazinyl-substituted quinolone carboxylic acid core and a fluorinated bicyclic aromatic system (quinolone with fluorine). Imatinib (Drug 2) includes a phenylaminopyrimidine scaffold and a methyl-substituted aniline ring. The provided interaction triple explicitly states that Ofloxacin forms hydrogen bonds with Imatinib. \n\nANSWER: Ofloxacin"}
{"custom_id": "Labetalol-Beta-3 adrenergic receptor_6:upper_bound", "response": "REASON: The question specifies the receptor encoded by ADRB3 (Beta-3 adrenergic receptor) and a drug that inhibits \u03b2- and \u03b1-adrenergic receptors. Labetalol is explicitly described as blocking both \u03b2- and \u03b1-adrenergic receptors, and the interaction triple confirms its binding and inhibition of the Beta-3 adrenergic receptor (ADRB3 gene product).  \nANSWER: Beta-3 adrenergic receptor"}
{"custom_id": "Cimetidine-Histamine H2 receptor_6:upper_bound", "response": "REASON: The question describes a protein coupled to Gs alpha subunit that stimulates cAMP production, which aligns with the Histamine H2 receptor's mechanism. The drug in question inhibits stomach acid production for treating heartburn/ulcers, matching cimetidine's function as an H2 antagonist. The provided interaction confirms cimetidine inhibits the Histamine H2 receptor.  \nANSWER: Histamine H2 receptor"}
{"custom_id": "chlortalidone-Sildenafil-Zaleplon_1:upper_bound", "response": "REASON: The question describes a sedative-hypnotic from the pyrazolopyrimidine class (indicated for insomnia) interacting with a PDE5 inhibitor (used for erectile dysfunction/PAH). Zaleplon is explicitly identified as a pyrazolopyrimidine-class sedative-hypnotic. The interaction triple \"Sildenafil-apoplexy-Zaleplon\" directly links these two drugs to an increased apoplexy risk. \n\nANSWER: Zaleplon"}
{"custom_id": "Cimetidine-Sumatriptan-Balsalazide_1:upper_bound", "response": "REASON: The question asks for a disease-modifying antirheumatic drug (DMARD) used in inflammatory bowel disease (IBD) that releases 5-aminosalicylic acid (5-ASA) in the large intestine and interacts with a triptan (serotonin 5-HT1B/1D agonist) to cause difficulty breathing. **Balsalazide** (Drug 3) matches the description as a DMARD delivering 5-ASA to the colon for IBD. **Sumatriptan** (Drug 2) is the triptan-class drug. The interaction triple explicitly states \"Sumatriptan-Difficulty breathing-Balsalazide,\" confirming the adverse reaction. \n\nANSWER: Balsalazide"}
{"custom_id": "Cimetidine-Labetalol-Alpha-1D adrenergic receptor_7:upper_bound", "response": "REASON: The question asks for the specific receptor inhibited by a blood pressure medication that blocks \u03b2- and \u03b1-adrenergic receptors. Labetalol is described as blocking \u03b2- and \u03b1-adrenergic receptors. The provided drug-protein interaction explicitly states \"Labetalol-binding and inhibition-Alpha-1D adrenergic receptor,\" confirming the inhibited receptor.  \nANSWER: Alpha-1D adrenergic receptor"}
{"custom_id": "Famotidine-Ticlopidine_3:upper_bound", "response": "REASON: The question describes Drug 1 with a thiazole ring fused to a guanidine group and a sulfonamide moiety. Famotidine's SMILES confirms these features: thiazole (S1-containing ring), guanidine (N=C(N)N), and sulfonamide (SO2N). Drug 2 has a benzene ring with chlorine and a thienopyridine skeleton, matching Ticlopidine's SMILES. The interaction triple states Famotidine participates in hydrogen bonding with Ticlopidine. Famotidine\u2019s sulfonamide (NH2) and guanidine (NH groups) act as hydrogen bond donors, while Ticlopidine lacks typical H-bond donors but may have acceptors (e.g., Cl or S). Thus, Famotidine is the hydrogen bond donor/acceptor in the interaction.  \nANSWER: Famotidine"}
{"custom_id": "Naproxen-Cetirizine-Salmeterol_4:upper_bound", "response": "REASON: The question asks which drug acts as the hydrogen bond acceptor when the piperazine-containing molecule (Cetirizine) is the donor. The interaction triples show that Cetirizine (piperazine-containing) is the subject in \"Cetirizine-Hydrogen bonding-Salmeterol,\" indicating it donates a hydrogen bond. Salmeterol, with oxygen-rich groups (e.g., hydroxyl, ether) in its SMILES, serves as the acceptor. \n\nANSWER: Salmeterol"}
{"custom_id": "phenytoin-Dapsone-Pyrimethamine-Muscarinic acetylcholine receptor M1_8:upper_bound", "response": "REASON: The question specifies identifying a neural cell-surface receptor in the CNS and exocrine glands bound to Gq proteins, inhibited by the third drug (a folic acid antagonist for protozoal DNA synthesis). The **PROTEIN BACKGROUND INFORMATION** identifies the **Muscarinic acetylcholine receptor M1** as localized to the CNS and exocrine glands, coupled to Gq proteins. The **DRUG 3 - PROTEIN INTERACTION TRIPLE** explicitly states that Pyrimethamine (the protozoal folic acid antagonist) binds and inhibits this receptor. \n\nANSWER: Muscarinic acetylcholine receptor M1"}
{"custom_id": "Ziprasidone-Desloratadine-Telithromycin_1:upper_bound", "response": "REASON: The interaction triple states that Desloratadine (Drug 2) interacts with Telithromycin (Drug 3) to cause sinus headache. Since the question asks which drug introduced to the regimen increases this risk via interaction with the allergy medication (Desloratadine), Telithromycin is the responsible entity.\nANSWER: Telithromycin"}
{"custom_id": "Naproxen-Carvedilol_3:upper_bound", "response": "REASON: The interaction is Naproxen (donor) \u2192 Carvedilol (acceptor). Naproxen's carboxylic acid (-COOH) donates a hydrogen (H-bond donor), while Carvedilol's ether oxygen (in the aryloxypropanol side chain) acts as the H-bond acceptor due to its lone pairs. The SMILES of Carvedilol includes ether (O) and hydroxyl groups, but the ether oxygen is a better acceptor under physiological conditions.  \nANSWER: Carvedilol"}
{"custom_id": "Candesartan-mitomycin C-vincristine-Torasemide_5:upper_bound", "response": "REASON: The question describes a drug with a chlorobenzenesulfonamide group attached to a pyridine ring and a urea linkage. Among the options, **Torasemide (Drug 4)** matches the urea linkage (NC(=O)NC(C)C in SMILES) and a sulfonamide group (S(=O)(=O)N) attached to a pyridine ring. While the provided SMILES for Torasemide shows a methylbenzene instead of chlorobenzene, the interaction triple specifies that **vincristine** (an alkaloid containing indole and catharanthine moieties) forms a hydrogen bond with Torasemide. This aligns with the question's requirement for the drug receiving a hydrogen bond from such an alkaloid. The structural mismatch in the SMILES may be an error, but the interaction data confirms the answer.\n\nANSWER: Torasemide"}
{"custom_id": "Gabapentin-Amiloride_0:upper_bound", "response": "REASON: The interaction triple specifies \"Gabapentin-weight gain-Amiloride,\" indicating Gabapentin is associated with weight gain when combined with Amiloride. While Amiloride primarily affects electrolyte balance (e.g., hyperkalemia), Gabapentin is independently linked to weight gain as a documented adverse effect, which may be exacerbated by drug interactions. The combination could potentiate metabolic effects, leading to increased weight.\n\nANSWER: Gabapentin"}
{"custom_id": "Fentanyl-Trazodone_3:upper_bound", "response": "REASON: Fentanyl has a propionyl group with a carbonyl oxygen (potential acceptor) but its piperidine amine is likely protonated (donor). Trazodone contains a triazolopyridine core with pyridine/triazole nitrogens and a carbonyl oxygen, all strong acceptors. The interaction triple indicates Fentanyl (donor) forms a hydrogen bond with Trazodone (acceptor).  \nANSWER: Trazodone"}
{"custom_id": "Lidocaine-vincristine-Torasemide_4:upper_bound", "response": "REASON: The question describes a drug with a methylated aniline core linked to a sulfonylurea group and a phenyl-pyridine structure. Torasemide's SMILES (CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C) matches this: the aniline (benzene with NH) connects to a pyridine (C=NC=C2) and a sulfonylurea (S(=O)(=O)NC(=O)N). The interaction triples indicate vincristine (bis-indole alkaloid) hydrogen-bonds with Torasemide, which aligns with the question's description of the target drug interacting with the bis-indole alkaloid. Lidocaine, while interacting with vincristine, lacks the sulfonylurea and phenyl-pyridine features described.  \nANSWER: Torasemide"}
{"custom_id": "Carvedilol-Dobutamine_0:upper_bound", "response": "REASON: The question asks for the nonselective beta-blocker with alpha-1 antagonism that interacts with a \u03b21-adrenergic agonist (dobutamine) to cause hepatitis. The interaction triple explicitly links carvedilol and dobutamine via hepatitis. Carvedilol matches the described pharmacological profile (nonselective beta-blocker with alpha-1 antagonism), while dobutamine is the synthetic \u03b21 agonist. The hepatitis risk is the specified interaction.  \nANSWER: Carvedilol"}
{"custom_id": "Citalopram-Zolpidem_0:upper_bound", "response": "REASON: The question specifies a nonbenzodiazepine Z-drug sleep aid acting as a GABA<sub>A</sub> receptor modulator prescribed for short-term insomnia management. Zolpidem is explicitly described as fulfilling this role, while citalopram is the SSRI for depression. The interaction triple confirms zolpidem as the insomnia agent in the context of adenopathy association.\nANSWER: Zolpidem"}
{"custom_id": "Fentanyl-Labetalol-Alpha-2A adrenergic receptor_7:upper_bound", "response": "REASON: The question describes a drug used for hypertension and pregnancy-related high blood pressure that blocks \u03b2- and \u03b1-adrenergic receptors. Labetalol matches this description. According to the provided DRUG 2 - PROTEIN INTERACTION TRIPLE, Labetalol binds to and inhibits the \"Alpha-2A adrenergic receptor,\" as explicitly stated in the interaction data, despite potential discrepancies with standard pharmacological understanding of Labetalol's primary \u03b11-blocking activity.  \nANSWER: Alpha-2A adrenergic receptor"}
{"custom_id": "Fluorouracil-Fulvestrant_3:upper_bound", "response": "REASON: Fluorouracil contains amide groups (NH) which can act as hydrogen bond donors, while Fulvestrant has a phenolic -OH group (another donor) and sulfonyl/carbonyl acceptors. The provided interaction triple (Fluorouracil-Hydrogen Bonding-Fulvestrant) implies Fluorouracil is the donor in this specific interaction, likely via its NH groups bonding to Fulvestrant's acceptors (e.g., sulfonyl oxygens).\n\nANSWER: Fluorouracil"}
{"custom_id": "Zolpidem-vincristine_3:upper_bound", "response": "REASON: Vincristine (Drug 2) has a significantly larger and more complex molecular structure with multiple bulky methoxy ester groups, indole moieties, and a multi-ringed scaffold. These features increase steric bulk compared to Zolpidem (Drug 1), which has a smaller fused imidazopyridine core and a single substituted toluene ring. Larger, multi-substituted molecules are more prone to steric clashes due to their three-dimensional complexity.  \nANSWER: vincristine"}
{"custom_id": "Cimetidine-hydroxychloroquine_3:upper_bound", "response": "REASON: The question describes a drug with a quinoline ring (a bicyclic structure with a benzene fused to a pyridine), chlorine substituent, and terminal ethanol group. Hydroxychloroquine (DRUG 2) matches this structure, as its SMILES includes a quinoline core (C=CC(=CC2=NC=C1)Cl) with a chlorine atom and a terminal ethanol group (CCO). The histamine H2 receptor antagonist described (guanidine and cyano groups) corresponds to Cimetidine (DRUG 1), whose SMILES contains NC(=NC)NC#N (guanidine and cyano moieties). Hydrogen bonding between Cimetidine (donor via guanidine NH groups) and hydroxychloroquine (acceptor via ethanol oxygen or quinoline nitrogen) aligns with the interaction triple provided.  \nANSWER: hydroxychloroquine"}
{"custom_id": "Naproxen-Zolpidem-vincristine-Torasemide_5:upper_bound", "response": "REASON: The question seeks a drug with a phenyl-substituted pyridine ring and sulfonylurea group capable of hydrogen bonding with a molecule containing indole and catharanthine systems. Torasemide (Drug 4) has a phenyl-pyridine structure (NC\u2082=C(C=NC=C\u2082)) and a sulfonylurea group (S(=O)(=O)NC(=O)NC(C)C). Vincristine (Drug 3), with indole and catharanthine systems, interacts with Torasemide via hydrogen bonding according to the provided interaction triple. \n\nANSWER: Torasemide"}
{"custom_id": "Citalopram-Isoniazid-Emtricitabine_4:upper_bound", "response": "REASON: The question describes three entities. The target compound has a sulfur-containing oxathiolane ring and fluorinated pyrimidine base, matching Emtricitabine's SMILES (OC(S1)CO for oxathiolane, N2C=C(C(=NC2=O)N)F for fluorinated pyrimidine). The hydrazide-substituted pyridine drug (Isoniazid, with C(=O)NN group) interacts with both Emtricitabine (via DRUG 2-DRUG 3 interaction) and Citalopram (tertiary amine with nitrile and fluorobenzene). The interaction triples confirm Isoniazid hydrogen-bonds with Emtricitabine, making Emtricitabine the answer.\n\nANSWER: Emtricitabine"}
{"custom_id": "Carbachol-Muscarinic acetylcholine receptor M5_6:upper_bound", "response": "REASON: The question specifies a G protein-coupled receptor activated by a cholinomimetic ophthalmic solution mimicking acetylcholine. Carbachol, a cholinergic agonist used in ophthalmic solutions, binds and activates muscarinic acetylcholine receptors. Among these, the Muscarinic acetylcholine receptor M5 (CHRM5) is a G protein-coupled receptor (GPCR) primarily found in the nervous system. The interaction triple confirms Carbachol activates M5, and the drug's hazardous classification aligns with the provided overdose context.  \nANSWER: Muscarinic acetylcholine receptor M5"}
{"custom_id": "acetazolamide-Haloperidol-Rosiglitazone-Bimatoprost_2:upper_bound", "response": "REASON: The PPAR\u03b3 agonist in question is Rosiglitazone (DRUG 3). The ophthalmic medication described (indicated for high intraocular pressure, increases eyelash size, causes dry/red eyes) aligns with Bimatoprost (DRUG 4). The interaction triple \"Rosiglitazone-Adenopathy-Bimatoprost\" directly indicates that concurrent use of Bimatoprost with Rosiglitazone increases the risk of adenopathy.  \nANSWER: Bimatoprost"}
{"custom_id": "Naproxen-alendronic acid_0:upper_bound", "response": "REASON: The question asks for a COX-inhibiting medication that can exacerbate gastric inflammation when used with a bisphosphonate. Naproxen, as a non-selective NSAID, inhibits COX-1 and COX-2, reducing protective gastric prostaglandins and increasing gastrointestinal risk. Alendronic acid (a bisphosphonate) is associated with esophageal/gastric irritation. Their combined use amplifies gastric mucosal damage potential.  \nANSWER: Naproxen"}
{"custom_id": "Aciclovir-Doxazosin-Alpha-1B adrenergic receptor_7:upper_bound", "response": "REASON: The question describes a quinazoline-class drug used for hypertension and BPH, which aligns with Doxazosin (DRUG 2). Doxazosin is a selective \u03b11-adrenergic blocker. The receptor in question is linked to the ADRA1B gene, which encodes the Alpha-1B adrenergic receptor. The provided PROTEIN BACKGROUND confirms that the Alpha-1B adrenergic receptor (ADRA1B) has a crystal structure with the inverse agonist (+)-cyclazosin, matching the drug's described mechanism of binding and inhibition.  \nANSWER: Alpha-1B adrenergic receptor"}
{"custom_id": "Risedronic acid-Zolpidem_3:upper_bound", "response": "REASON: Risedronic acid contains two phosphonic acid groups (P(=O)(O)O) with multiple hydroxyl (-OH) groups, which are strong hydrogen bond donors and acceptors. Zolpidem contains an imidazo[1,2-a]pyridine core and a terminal amide (CC(=O)N(C)C), where the carbonyl oxygen (C=O) acts as a hydrogen bond acceptor. The drug-drug interaction triple explicitly states Risedronic acid as the hydrogen bond donor in the interaction, implying its hydroxyl groups donate hydrogen bonds to Zolpidem's acceptor groups (e.g., carbonyl oxygen or aromatic nitrogen lone pairs). \n\nANSWER: Risedronic acid"}
{"custom_id": "Amlodipine-vincristine_0:upper_bound", "response": "REASON: The question specifies a dihydropyridine calcium channel blocker (amlodipine) co-administered with a microtubule-disrupting chemotherapeutic agent (vincristine), resulting in an increased white blood cell count. The provided drug-drug interaction triple explicitly states that amlodipine increases this effect in the context of vincristine use. Vincristine is the microtubule-targeting agent associated with neurotoxicity and cancer therapy, making it the entity in question.  \nANSWER: vincristine"}
{"custom_id": "Temazepam-Trimipramine-Histamine H1 receptor_7:upper_bound", "response": "REASON: The question identifies a tricyclic antidepressant (TCA) with weak monoamine reuptake inhibition but significant antihistamine effects, causing additive constipation when combined with temazepam. Trimipramine is described as an atypical TCA due to its weak monoamine reuptake inhibition and strong antihistamine activity. The protein in question is a G-protein-coupled receptor (GPCR) involved in anti-allergy responses, located in smooth muscle, vascular endothelium, and the CNS. Histamine H1 receptor is a GPCR mediating allergic responses, and trimipramine\u2019s antihistamine effects align with its inhibition of this receptor, as confirmed by the drug-protein interaction triple.  \nANSWER: Histamine H1 receptor"}
{"custom_id": "Naproxen-Risedronic acid-vincristine-Torasemide_2:upper_bound", "response": "REASON: The interaction triple between vincristine (Drug 3) and Torasemide (Drug 4) explicitly states \"vincristine-drug toxicity NOS-Torasemide,\" indicating Torasemide increases the risk of unspecified drug toxicity when combined with vincristine. The clinical context involves a patient on vincristine (the specified vinca alkaloid) starting Torasemide (the sulfonamide loop diuretic) for fluid overload, aligning with the interaction data provided. Other triples (e.g., Naproxen-Risedronic acid or Risedronic acid-vincristine) do not directly address the toxicity risk between the chemotherapy and the diuretic. \n\nANSWER: Torasemide"}
{"custom_id": "Duloxetine-desvenlafaxine_3:upper_bound", "response": "REASON: Duloxetine contains a secondary amine group (N-methylpropanamine) with a hydrogen atom attached to the nitrogen, enabling it to act as a hydrogen bond donor. Desvenlafaxine has two hydroxyl (-OH) groups, which are hydrogen bond donors, and a tertiary amine (N,N-dimethylaminoethyl) that can act as an acceptor. The interaction described in the triple (Duloxetine-Hydrogen Bonding-desvenlafaxine) implies Duloxetine donates a hydrogen bond, likely from its secondary amine, to desvenlafaxine's tertiary amine (acceptor).  \nANSWER: Duloxetine"}
{"custom_id": "Aciclovir-Dipyridamole_0:upper_bound", "response": "REASON: The question asks for the antiviral medication associated with herpesviruses and gastrointestinal side effects that can cause skin eruptions when taken with a nucleoside transport/PDE3 inhibitor antiplatelet/vasodilator. Aciclovir matches the antiviral profile and GI side effects. Dipyridamole is the interacting drug (nucleoside transport/PDE3 inhibitor). The provided drug-drug interaction triple explicitly links Aciclovir as the subject causing the eruption (predicate) when combined with Dipyridamole (object).  \nANSWER: Aciclovir"}
{"custom_id": "Celecoxib-Palonosetron_0:upper_bound", "response": "REASON: The question asks for the COX-2 inhibitor medication linked to an increased risk of cellulitis when combined with a 5-HT3 antagonist (Palonosetron). The provided drug-drug interaction triple explicitly states \"Celecoxib-cellulitis-Palonosetron,\" confirming Celecoxib as the answer. Celecoxib\u2019s role as a selective COX-2 inhibitor aligns with the question\u2019s requirements.\nANSWER: Celecoxib"}
{"custom_id": "Methylphenidate-Modafinil-Pamidronic acid-thiotepa_5:upper_bound", "response": "REASON: The compound described with a phosphorothioate (P=S) group and three aziridine rings matches **thiotepa** (DRUG 4, SMILES: `C1CN1P(=S)(N2CC2)N3CC3`). The molecule with two phosphonic acid groups (P(=O)(O)O) and a primary amine is **Pamidronic acid** (DRUG 3). According to the interaction triple, Pamidronic acid hydrogen bonds to thiotepa. The question asks for the compound (thiotepa) that forms this bond with Pamidronic acid, consistent with the interaction directionality in the provided data.\n\nANSWER: thiotepa"}
{"custom_id": "Desloratadine-solifenacin_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided states \"Desloratadine-bursitis-solifenacin,\" indicating that desloratadine is associated with bursitis as part of its interaction with solifenacin. The triple structure (subject-predicate-object) positions desloratadine as the entity linked to bursitis in the context of this interaction.  \nANSWER: Desloratadine"}
{"custom_id": "Naproxen-hydroxychloroquine_3:upper_bound", "response": "REASON: The question specifies a drug with a carboxylic acid (functional group -COOH) attached to a naphthalene ring system. Drug 1 (Naproxen) matches this description, as its SMILES includes a naphthalene moiety (two fused benzene rings) and a carboxylic acid group (-C(=O)O). The interaction involves hydrogen bonding, which typically occurs between a hydrogen bond donor (e.g., -OH, -NH) and acceptor (e.g., carbonyl oxygen, lone pairs on electronegative atoms). Naproxen's carboxylic acid can act as both a donor (via its -OH) and acceptor (via its carbonyl oxygen). Drug 2 (hydroxychloroquine) contains a quinoline ring (fused benzene-pyridine system) substituted with chlorine and a secondary amine (-NH-), which can also participate in hydrogen bonding. The provided triple confirms the hydrogen bonding interaction between Naproxen and hydroxychloroquine, with Naproxen being the entity featuring the carboxylic acid group.  \nANSWER: Naproxen"}
{"custom_id": "Citalopram-Fenofibrate_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided explicitly links Citalopram (SSRI) and Fenofibrate (PPAR\u03b1 agonist) to cholecystitis. Fenofibrate\u2019s background highlights its association with cholelithiasis, a direct risk factor for cholecystitis. When combined with Citalopram, the risk of cholecystitis is amplified, likely due to additive effects on gallbladder pathology. The interaction triple\u2019s structure (Citalopram-cholecystitis-Fenofibrate) indicates that the combination of these two drugs increases the risk, with Fenofibrate\u2019s inherent gallbladder-related adverse effects being the primary contributor.  \nANSWER: Fenofibrate"}
{"custom_id": "Telmisartan-Cinacalcet_0:upper_bound", "response": "REASON: The drug-drug interaction triple provided specifies \"Telmisartan-dysarthria-Cinacalcet,\" indicating that Telmisartan is the agent associated with causing dysarthria when interacting with Cinacalcet. While neither drug's individual background information explicitly lists dysarthria as a common adverse effect, the interaction triple directly links Telmisartan to this manifestation in the context of concurrent use with Cinacalcet. This suggests a potential synergistic or additive mechanism (e.g., electrolyte imbalances, hypotension, or hypocalcemia-related neuromuscular effects) leading to the neurological symptom.\nANSWER: Telmisartan"}
{"custom_id": "Rofecoxib-Torasemide_3:upper_bound", "response": "REASON: Torasemide contains sulfonamide (-SO\u2082NH-) and urea (-NC(=O)NC-) groups with NH moieties that can act as hydrogen bond donors, while Rofecoxib lacks traditional H-bond donors (no -OH/-NH groups) and primarily has acceptors (sulfonyl and carbonyl oxygens). The interaction triple confirms hydrogen bonding between them, but structural analysis indicates Torasemide's NH groups are the likely donors.  \nANSWER: Torasemide"}
{"custom_id": "Lamotrigine-Dexpramipexole_3:upper_bound", "response": "REASON: Hydrogen bond donors require a hydrogen atom bonded to an electronegative atom (e.g., N, O). Dexpramipexole contains a primary amine (-NH\u2082) in its tetrahydrobenzothiazine structure (terminal N in SMILES: SC(=N2)N), which has two hydrogen atoms available for donation. Lamotrigine's triazine-2,4-diamine scaffold includes aromatic amines (N-H groups) on an electron-deficient triazine ring, where lone pairs are partially delocalized into the ring, reducing their hydrogen-bond-donating capacity compared to a primary amine. Primary amines like dexpramipexole\u2019s -NH\u2082 are stronger donors than aromatic amines in electron-poor systems. \n\nANSWER: Dexpramipexole"}
{"custom_id": "Alprazolam-Doxazosin_0:upper_bound", "response": "REASON: The question specifies a drug interacting with a selective \u03b11-adrenergic blocker (Doxazosin) via myelodysplasia, where the interacting drug is a potent GABA_A-receptor-acting anxiolytic. Alprazolam matches this profile as a benzodiazepine targeting GABA_A receptors and is explicitly linked to Doxazosin in the interaction triple provided.  \nANSWER: Alprazolam"}
{"custom_id": "Ciclopirox-hydroxychloroquine_0:upper_bound", "response": "REASON: The question asks for the drug indicated for malaria prophylaxis and autoimmune diseases (lupus) associated with adenopathy risk when combined with a topical antifungal (Ciclopirox, used for onychomycosis and seborrheic dermatitis). The provided interaction triple explicitly links Ciclopirox and hydroxychloroquine with adenopathy. Hydroxychloroquine matches the described indications (malaria, lupus) and is the object in the interaction triple, indicating it is the drug at risk.\nANSWER: hydroxychloroquine"}
{"custom_id": "alendronic acid-Ibuprofen_3:upper_bound", "response": "REASON: The question specifies a drug with two phosphonic acid groups (each with hydroxyl substituents) and a drug with a carboxylic acid on an isobutylbenzene core. Alendronic acid (Drug 1) has two phosphonic acid groups (-P(=O)(O)O) with hydroxyls, matching the first description. Ibuprofen (Drug 2) has a carboxylic acid (-C(=O)O) and an isobutylbenzene structure. The interaction triple explicitly states that alendronic acid participates in hydrogen bonding with ibuprofen, mediated by the hydroxyl groups of alendronic acid\u2019s phosphonic acids and the carboxylic acid of ibuprofen.  \nANSWER: alendronic acid"}
{"custom_id": "Celecoxib-Labetalol-Metoprolol-Gastrin-releasing peptide receptor_8:upper_bound", "response": "REASON: The question specifies a cardioselective \u03b21-adrenergic receptor antagonist affected by CYP2D6 variability (Metoprolol) and a pancreatic-expressed protein involved in gastrointestinal hormone regulation and cell proliferation. The **Metoprolol-binding and activation-Gastrin-releasing peptide receptor** triple confirms this interaction. The protein's background matches the described functions and expression.  \nANSWER: Gastrin-releasing peptide receptor"}
{"custom_id": "Duloxetine-Darunavir_0:upper_bound", "response": "REASON: The interaction triple provided explicitly states that Duloxetine is associated with narcolepsy when interacting with Darunavir. Darunavir is the antiretroviral protease inhibitor requiring pharmacokinetic boosting (e.g., with ritonavir/cobicistat). The question asks for the drug causing increased narcolepsy risk when co-administered with such a boosted protease inhibitor, which aligns with the Duloxetine-Darunavir interaction.\nANSWER: Duloxetine"}
{"custom_id": "Minoxidil-Perindopril_3:upper_bound", "response": "REASON: Perindopril contains multiple carbonyl groups (ester, amide, carboxylic acid), whose oxygen atoms are strong hydrogen bond acceptors. Minoxidil primarily has an N-oxide oxygen (acceptor) and amine groups (likely protonated as donors). The abundance of carbonyl oxygens in Perindopril makes it the more probable acceptor.  \nANSWER: Perindopril"}
{"custom_id": "Oxaprozin-Sildenafil_3:upper_bound", "response": "REASON: The question describes Drug 1 with a fused benzoxazole core (evident in Oxaprozin\u2019s SMILES structure: O=C(O)CCC2=NOc1ccccc1c2c3ccccc3) and a biaryl system (two benzene rings in its structure). The \u03c0-\u03c0 stacking interaction partner, Drug 2, contains a pyrazolopyrimidinone scaffold and sulfonamide-substituted piperazine (matching Sildenafil\u2019s SMILES). The provided interaction triple explicitly states Oxaprozin-\u03c0-\u03c0 Stacking-Sildenafil.\nANSWER: Oxaprozin"}
{"custom_id": "Ibuprofen-Repaglinide_3:upper_bound", "response": "REASON: Ibuprofen contains a propionic acid (carboxylic acid) group (C(=O)O), which at physiological pH is deprotonated (COO\u207b), acting as a hydrogen bond acceptor. Repaglinide has an amide group (NH) that can donate hydrogen bonds. The documented interaction (Ibuprofen-Hydrogen Bonding-Repaglinide) implies a hydrogen bond forms between the two drugs. Chemically, Repaglinide's amide NH (donor) donates a hydrogen bond to Ibuprofen's deprotonated carboxylate (acceptor). The triple's structure does not inherently specify donor/acceptor roles, but structural analysis confirms Repaglinide is the donor.  \nANSWER: Repaglinide"}
{"custom_id": "Trazodone-Alpha-2C adrenergic receptor_6:upper_bound", "response": "REASON: The question specifies a phenylpiperazine antidepressant used for major depressive disorder, anxiety, and insomnia, which matches **Trazodone**. The protein inhibited by Trazodone, per the interaction triple, is the **Alpha-2C adrenergic receptor**, a human gene-encoded alpha-2 adrenergic receptor.\nANSWER: Alpha-2C adrenergic receptor"}
